Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 92,832

Document Document Title
WO/2024/035545A1
Provided are methods for: removing cardiac cells impaired or functionally diminished by stress or age, wherein optionally cardiac cells impaired or functionally diminished have reduced proliferative capacity and/or polyploidy, initiating...  
WO/2024/033459A1
The present invention relates to pharmaceutical compositions comprising 5-ethyl-4- methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.  
WO/2024/031997A1
The present invention relates to N-N-bis-oxazolidinone alkaloid compounds, a preparation method and a use in the medical field. The present invention provides two new N-N-bis-oxazolidinone alkaloid isomers isolated and purified from Loni...  
WO/2024/035035A1
The present invention relates to a pharmaceutical composition for preventing or treating a degenerative valvular disease such as aortic stenosis, and has been completed by confirming that, when protein-arginine deiminase (PAD) proteins a...  
WO/2024/028192A1
The present invention relates to CRP-binding phosphocholine-HSA conjugates and their use for binding and/or neutralizing CRP in the blood flow. The phosphocholine-HSA conjugates according to the invention are specifically useful in the t...  
WO/2024/028782A1
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relat...  
WO/2024/027694A1
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...  
WO/2024/031016A1
Methods for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) an...  
WO/2024/027809A1
The present invention pertains to the field of biopharmaceutics, and particularly relates to an RNA inhibitor for inhibiting APOC3 gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor comprises a sense strand ...  
WO/2024/027641A1
An IRAK4 inhibitor composition, a preparation method therefor and use thereof. The composition comprises: (i) a compound of formula I, a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof; (ii) a diluent; (iii) a disin...  
WO/2024/028808A1
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...  
WO/2024/027593A1
The present invention relates to use of a Jun inhibitor in preparing a medicament for treating heart failure with preserved ejection fraction (HFpEF).  
WO/2024/027521A1
Provided are a methylophiopogonone A derivative, and the preparation and the use thereof. The present invention specifically relates to three derivatives of methylophiopogonone A, which derivatives have the chemical structures of formula...  
WO/2024/030080A1
The present invention generally relates to recombinant polypeptides capable of regulating actin remodelling. In particular, the polypeptides disclosed herein are selective for ADP-actin and may modulate ADP-actin remodelling under energy...  
WO/2024/027779A1
Provided are a new crystal form of an ARNi compound, a preparation method therefor, and use thereof.  
WO/2024/027116A1
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...  
WO/2024/027750A1
Provided herein are methods of treating pulmonary hypertension, particularly pulmonary arterial hypertension (PAH) pulmonary arterial hypertension in a subject, comprising administering to the subject in need thereof a BTK inhibitor, or ...  
WO/2024/030615A1
The disclosure provides methods of treating hypertension in a subject in need thereof, comprising administering baxdrostat.  
WO/2024/029599A1
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methox yphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolid ine-3-yl]-5-(trifluoromethyl)phenyl}p...  
WO/2024/026058A1
The present invention provides crystalline forms of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2 H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4( 1H,3H)-dione ("Compound I"). Also provided are related pharmace...  
WO/2024/023196A1
The present invention relates to the use of Antithrombin in the treatment of stroke.  
WO/2024/026290A1
The present invention relates to compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions of the compounds, or salts thereof, that can inhibit secreted phospholipases A2 (sPLA2-X) enzymes, wherein th...  
WO/2024/026444A1
Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leuci...  
WO/2024/024565A1
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...  
WO/2024/025817A1
Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrid o[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use t...  
WO/2024/023369A1
The present application is directed to an anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment or prevention of shock in a patient, wherein said patient is characterized by...  
WO/2023/238952A9
The present invention provides a pharmaceutical composition containing a pharmaceutically acceptable salt of (2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)ace tic acid (compound B) with good storage stability. The present in...  
WO/2024/023360A1
The present invention provides IP5 substituted compounds of general formula I, their methods of synthesis and their uses. The IP5 substituted compounds of the invention are characterized for having -O(alkyl)nX, and -O(alkyl)yCy(alkyl)y'-...  
WO/2024/021024A1
A heart-protecting factor miR-139-3p and use thereof. Provided is use of miR-139-3p in the preparation of a formulation for regulating and controlling macrophage polarization. Also provided are use of a reagent material that overexpresse...  
WO/2024/022481A1
The present invention belongs to the technical field of medicines. Disclosed are phenyl-substituted dihydronaphthyridine compounds and preparation and use thereof. The compound disclosed by the present invention is represented by formula...  
WO/2024/022382A1
An osmotic pump controlled release preparation, which comprises the following structures sequentially arranged from inside out: a tablet core containing a drug-containing layer and a push layer, a controlled-release coating layer having ...  
WO/2024/021429A1
The present invention belongs to the field of biotechnology, and particularly relates to a gene delivery system targeting retina and use thereof. The gene delivery system targeting retina comprises an adeno-associated virus vector rAAV11...  
WO/2024/025953A2
Disclosed are methods for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, or cancer. Also disclosed is a method of enhancing cancer immunotherapy.  
WO/2024/023710A1
The present invention provides a pharmaceutical composition which is a tablet comprising tafamidis free acid, one or more diluents, 7-9% (w/w%) disintegrant and a lubricant. A representative example is a tablet comprising about 11.6% (w/...  
WO/2024/023312A1
There is provided inter alia a pharmaceutical formulation comprising a catechin component for use in the treatment or prevention of diabetic cardiomyopathy.  
WO/2024/023068A1
The present invention concerns the use of a molecule chosen from a globin, a globin protomer or an extracellular hemoglobin of Annelids, for treating and/or preventing at least one complement-activation associated disease, preferably isc...  
WO/2024/023295A1
The application relates to a pharmaceutical composition comprising Imatinib and a stabilizing formulation, wherein said stabilizing formulation comprises a bulking agent and a buffering agent, wherein the pH of the pharmaceutical composi...  
WO/2024/020468A1
Methods for treating non-obstructive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with mid- ventricular obstruction (MVO) are described herein. The treatment methods include the administration of a cardiac myosin inhibitor ...  
WO/2024/019171A1
The purpose of the present invention is to provide a composition that improves conditions related to ocular blood flow by evaluating effects on ocular blood flow. Provided is a composition for improving and/or maintaining ocular blood fl...  
WO/2024/019080A1
The present invention provides: a method for producing umbilical cord-derived mesenchymal cells that highly express a vascular endothelial growth factor, the method comprising a step for culturing an umbilical cord-derived mesenchymal st...  
WO/2024/017331A1
The present invention belongs to the fields of bioengineering and biological treatment. Disclosed are an anti-ADM monoclonal antibody or a fragment thereof and a pharmaceutical composition, a detection reagent, or a kit comprising the mo...  
WO/2024/017423A1
The invention relates to a peptide identified as SEQ ID NO: 1, for use in the manufacture of a medicine for the treatment of a disease associated with apolipoprotein A-l (Apo-Al) or transthyretin (TTR) involvement. In particular, the pep...  
WO/2024/016935A1
The present invention belongs to the field of functional emulsions. Disclosed is a method for improving the embedding rates of ginsenosides Rg3 and CK and the stability of a nanoemulsion. The method for improving the embedding rates of r...  
WO/2024/019661A1
The present disclosure concerns a method of promoting the ubiquitination of MK2 protein, comprising contacting the MK2 protein with a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof. The present disclosure als...  
WO/2024/019509A1
The present invention provides a pharmaceutical composition for preventing or treating metabolic diseases comprising a novel pan-PPAR agonist compound or a salt thereof as an active ingredient. As a pan-PPAR agonist, the compound or the ...  
WO/2024/017144A1
Provied are a class of substituted imidazo[1,2-a]pyridine compounds, pharmaceutical compositions containing the same, and use of the compounds in the treatment and prevention of fibrosis.  
WO/2024/017915A1
The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine ...  
WO/2024/017257A1
The present application relates to an aromatic substituent-containing heteroaryl- or phenyl-imidazole compound, and a stereoisomer, hydrate, solvate, pharmaceutically-acceptable salt or prodrug thereof. The present application also relat...  
WO/2024/017366A1
Provided are a compound of formula (I) having an effect of regulating and controlling the activity of 15-PGDH, a stereoisomer, a tautomer or a form of a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof...  
WO/2024/018440A1
Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA...  

Matches 101 - 150 out of 92,832